Gift Opening
$200 Off MarketBeat All Access
Thanks for being one of our best subscribers! You are eligible for a limited-time discount.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
Claim Your Discount
×
Free Trial
Thank you for registering! Take a moment to confirm your subscription to Insider Trades Newsletter so that you can access MarketBeat's tools, reports, and news. Please click the "Send Confirmation Email" button and we'll send you an email with confirmation instructions.
Send Confirmation Email
NASDAQ:CGON

CG Oncology (CGON) Stock Price, News & Analysis

→ This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad)
Free cgon Stock Alerts
$29.98
-0.99 (-3.20%)
(As of 05/17/2024 06:55 PM ET)
Compare
Today's Range
$29.27
▼
$31.69
50-Day Range
$25.84
▼
$43.90
52-Week Range
$25.77
▼
$50.23
Volume
603,200 shs
Average Volume
677,721 shs
Market Capitalization
$2.00 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$63.75
Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsSocial Media

CG Oncology MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
112.6% Upside
$63.75 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.43mentions of CG Oncology in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.71) to ($1.97) Per Share

Overall MarketRank™

New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.13 out of 5 stars

Medical Sector

773rd out of 914 stocks

Biological Products, Except Diagnostic Industry

132nd out of 153 stocks

See Top Rated MarketRank™ Stocks Here
CGON stock logo

About CG Oncology Stock (NASDAQ:CGON)

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

CGON Stock Price History

CGON Stock News Headlines

May 15, 2024 | americanbankingnews.com
CG Oncology (NASDAQ:CGON) Upgraded to "Buy" by The Goldman Sachs Group
May 14, 2024 | markets.businessinsider.com
Decoding 10 Analyst Evaluations For CG Oncology
May 14, 2024 | msn.com
Goldman Sachs Upgrades CG Oncology (CGON)
May 12, 2024 | americanbankingnews.com
CG Oncology (NASDAQ:CGON) Hits New 12-Month Low at $28.52
May 10, 2024 | markets.businessinsider.com
Buy Rating for CG Oncology on Strong Trial Results and Market Potential
May 9, 2024 | globenewswire.com
CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates
May 6, 2024 | markets.businessinsider.com
CG Oncology’s Cretostimogene Shows Promising Efficacy and Safety in NMIBC Treatment, Merits Buy Rating
May 6, 2024 | seekingalpha.com
CG Oncology: ASCO Play And Top-Line Data End Of 2024 Could Drive Further Value
May 4, 2024 | markets.businessinsider.com
Buy Rating Justified by CG Oncology’s Cretosmogene Efficacy and Market Positioning
May 3, 2024 | seekingalpha.com
CG Oncology reports data from Phase 3 bladder cancer study
May 3, 2024 | seekingalpha.com
CG Oncology's Promising Bladder Cancer Treatment: Balancing Hope And Risk In Late-Stage Trials
May 3, 2024 | globenewswire.com
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
April 26, 2024 | globenewswire.com
CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024
April 24, 2024 | nasdaq.com
Validea Detailed Fundamental Analysis - CGON
April 24, 2024 | globenewswire.com
CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024
April 23, 2024 | markets.businessinsider.com
Buy Rating Affirmed for CG Oncology Amidst Bladder Cancer Treatment Landscape and BCG Shortage
April 16, 2024 | finance.yahoo.com
CG Oncology, Inc. (CGON)
April 12, 2024 | msn.com
20 Countries with the Most Domestically Listed Companies in the World
April 5, 2024 | investing.com
CG Oncology Inc (CGON)
April 5, 2024 | markets.businessinsider.com
Buy Rating Affirmed for CG Oncology on Strong Clinical Data and Market Potential
April 1, 2024 | markets.businessinsider.com
Buy Rating Justified by CG Oncology’s Strong Clinical Trial Results and Promising Cretosimogene Therapy
March 28, 2024 | globenewswire.com
CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting
March 1, 2024 | seekingalpha.com
CGON CG Oncology, Inc.
February 28, 2024 | markets.businessinsider.com
Buy Rating Affirmed for CG Oncology, Inc. on Promising CG0070 Phase 3 Trials and Unmet Medical Need
February 27, 2024 | finance.yahoo.com
CG Oncology Announces First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-risk Non-Muscle Invasive Bladder Cancer
See More Headlines

Company Calendar

Today
5/20/2024
Next Earnings (Estimated)
8/08/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:CGON
Previous Symbol
NASDAQ:CGON
CUSIP
N/A
CIK
1991792
Web
cgoncology.com
Phone
949-419-6203
Fax
N/A
Employees
61
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$63.75
High Stock Price Target
$75.00
Low Stock Price Target
$50.00
Potential Upside/Downside
+112.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
57.95
Quick Ratio
57.95

Sales & Book Value

Annual Sales
$200,000.00
Price / Sales
9,989.34
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($1.94) per share
Price / Book
-15.45

Miscellaneous

Outstanding Shares
66,640,000
Free Float
N/A
Market Cap
$2.00 billion
Optionable
Optionable
Beta
N/A

Key Executives

  • Mr. Arthur Kuan (Age 33)
    Chairman & CEO
    Comp: $640.97k
  • Mr. Ambaw Bellete M.S. (Age 53)
    President & COO
    Comp: $1.06M
  • Dr. Vijay Kasturi M.D. (Age 56)
    Chief Medical Officer
    Comp: $212.24k
  • Ms. Corleen M. Roche (Age 57)
    CFO & Secretary
  • Ms. Amy Steele
    Vice President of Finance, Accounting & Administration
  • Mr. Swapnil Bhargava Ph.D.
    Chief Technical Officer
  • Mr. Bing Kung
    Vice President of Corporate Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CGON Stock Analysis - Frequently Asked Questions

Should I buy or sell CG Oncology stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CG Oncology in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CGON shares.
View CGON analyst ratings or view top-rated stocks.

What is CG Oncology's stock price target for 2024?

4 equities research analysts have issued 12-month price targets for CG Oncology's stock. Their CGON share price targets range from $50.00 to $75.00. On average, they expect the company's share price to reach $63.75 in the next year. This suggests a possible upside of 112.6% from the stock's current price.
View analysts price targets for CGON or view top-rated stocks among Wall Street analysts.

How have CGON shares performed in 2024?

CG Oncology's stock was trading at $37.17 at the start of the year. Since then, CGON shares have decreased by 19.3% and is now trading at $29.98.
View the best growth stocks for 2024 here.

When is CG Oncology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024.
View our CGON earnings forecast.

What ETFs hold CG Oncology's stock?

ETFs with the largest weight of CG Oncology (NASDAQ:CGON) stock in their portfolio include Principal Healthcare Innovators ETF (BTEC).Goldman Sachs Future Health Care Equity ETF (GDOC).

When did CG Oncology IPO?

CG Oncology (CGON) raised $380 million in an initial public offering (IPO) on Thursday, January 25th 2024. The company issued 20,000,000 shares at $19.00 per share.

When does the company's lock-up period expire?

CG Oncology's lock-up period expires on Tuesday, July 23rd. CG Oncology had issued 20,000,000 shares in its initial public offering on January 25th. The total size of the offering was $380,000,000 based on an initial share price of $19.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the expiration of the lock-up period.

Who are CG Oncology's major shareholders?

CG Oncology's stock is owned by many different institutional and retail investors. Top institutional shareholders include Decheng Capital LLC (8.19%), Vanguard Group Inc. (3.34%), BVF Inc. IL (2.83%), Janus Henderson Group PLC (2.28%), RA Capital Management L.P. (2.10%) and Price T Rowe Associates Inc. MD (1.49%). Insiders that own company stock include Corleen M Roche, Decheng Capital Global Life Sc, Hong Fang Song and Vijay Kasturi.
View institutional ownership trends.

How do I buy shares of CG Oncology?

Shares of CGON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CGON) was last updated on 5/20/2024 by MarketBeat.com Staff

From Our Partners
Exposed: 10 CENT Crypto to Explode May 20th?
True Market Insiders
The Overlooked Retirement Asset You Probably Don’t Own
Crypto 101 Media
This Apple-like Innovator is Revolutionizing Healthcare
Wall Street Star
Urgent Nvidia Warning
Altimetry
Shocking: One AI startup's revenue could surge 4,735%
Manward Press
Bill Gates is all about this tiny $2 stock
Timothy Sykes
CEO of Biggest AI Chipmaker Just Dropped a Bombshell…
Banyan Hill Publishing
Elon’s New Device is About to Shock the World
InvestorPlace